Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine, 25(11), 2120-7. presented at the 2007 Mar 01. doi:10.1016/j.vaccine.2006.11.016. (2007).
A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine. AIDS Res Hum Retroviruses, 24(6), 873-80. presented at the 2008 Jun. doi:10.1089/aid.2007.0292. (2008).
Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine, 26(22), 2788-95. presented at the 2008 May 23. doi:10.1016/j.vaccine.2008.02.071. (2008).
Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine. PLoS One, 5(1), e8816. presented at the 2010 Jan 25. doi:10.1371/journal.pone.0008816. (2010).
Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One, 5(1), e8617. presented at the 2010 Jan 25. doi:10.1371/journal.pone.0008617. (2010).
A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus. AIDS Res Hum Retroviruses, 26(8), 933-42. presented at the 2010 Aug. doi:10.1089/aid.2009.0242. (2010).
Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One, 5(9), e12873. presented at the 2010 Sep 21. doi:10.1371/journal.pone.0012873. (2010).
In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One, 6(5), e19252. presented at the 2011. doi:10.1371/journal.pone.0019252. (2011).
A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One, 7(8), e41936. presented at the 2012. doi:10.1371/journal.pone.0041936. (2012).
Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS One, 7(4), e33103. presented at the 2012. doi:10.1371/journal.pone.0033103. (2012).
Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. PLoS One, 8(9), e74314. presented at the 2013. doi:10.1371/journal.pone.0074314. (2013).
A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults. PLoS One, 10(5), e0125954. presented at the 2015. doi:10.1371/journal.pone.0125954. (2015).
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens. J Infect Dis, 215(1), 95-104. presented at the 2017 Jan 01. doi:10.1093/infdis/jiw500. (2017).